The partners aim to progress DRIVE’s EIDD-2801 into human clinical trials for Covid-19. Credit: Hal Gatewood on Unsplash.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Ridgeback Biotherapeutics and Emory University’s not-for-profit Drug Innovations at Emory (DRIVE) have partnered to develop a drug candidate for potential treatment of Covid-19.

The partners aim to progress DRIVE’s EIDD-2801 into human clinical trials.

EIDD-2801 is an orally bioavailable version of a ribonucleoside analogue that blocks the replication of various RNA viruses such as SARS-CoV2.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the alliance, Ridgeback obtained an exclusive licence for EIDD-2801 and will advance the candidate through clinical development to make it available for the ongoing pandemic.

DRIVE CEO George Painter said: “With EIDD-2801 close to entering clinical trials for influenza and its activity against the SARS and MERS coronaviruses, we immediately recognised that EIDD-2801 had the potential for treating Covid-19. Based on our extensive testing, we believe EIDD-2801 will be effective in treating individuals that have been sickened by Covid-19.

“Given Ridgeback Biotherapeutics’ experience in accelerating the development of potential therapeutics in outbreak settings and its proven commitment to global health, we are confident that Ridgeback can quickly advance EIDD-2801 into clinical trials for Covid-19 and initiate steps toward ensuring a rapid development path for this promising drug.”

EIDD-2801’s has been wholly or partially funded by the National Institute of Allergy and Infectious Diseases (NIAID) and the Defense Threat Reduction Agency (DTRA) to treat coronavirus, influenza, chikungunya and Venezuelan Equine Encephalitis Virus.